APTO — Aptose Biosciences Inc.

Summary of Aptose Biosciences Q1 2024 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: As of March 31, 2024, Aptose had approximately $9.3 million in cash and cash equivalents, unchanged from the end of 2023.
• Net Loss: The company reported a net loss of approximately $9.6 million, translating to a loss of $0.73 per share, an improvement from a loss of $13.7 million or $2.22 per share in Q1 2023.
• R&D Expenses: Research and development expenses were approximately $6.4 million, down from $8.8 million in the same quarter last year. Program costs for tuspetinib were $3.9 million, reduced from $4.8 million in Q1 2023.
• G&A Expenses: General and administrative expenses decreased to $3.3 million from $5.3 million year-over-year.

2. Strategic Updates and Business Highlights

• Clinical Focus: Aptose is advancing the development of tuspetinib (TUS) as a triplet therapy (TUS-VEN-HMA) for frontline treatment of newly diagnosed Acute Myeloid Leukemia (AML) patients. This strategy aims to improve response rates and survival outcomes.
• Clinical Trials: The protocol for the triplet therapy has been approved by the FDA, and patient enrollment is expected to start in mid-2024. Data from the triplet study is anticipated to be presented at the ASH 2024 conference.
• Safety Profile: Tuspetinib has demonstrated a favorable safety profile, with no significant drug-related adverse events reported in trials to date.

3. Forward Guidance and Outlook

• Milestones: Key upcoming milestones include:
  • Presentation of single-agent and doublet data at the EHA Meeting in June 2024.
  • Initiation of patient dosing in the triplet study in summer 2024.
  • Reporting of complete responses and safety data at ASH 2024.
  • Full enrollment of the triplet study expected in the first half of 2025.
• Regulatory Compliance: Aptose has regained compliance with NASDAQ listing rules, addressing previous concerns regarding stockholder equity.

4. Bad News, Challenges, or Points of Concern

• No Revenue: The company reported no revenues for Q1 2024, continuing its reliance on funding from equity and financing activities.
• Ongoing Compliance Issues: Despite regaining compliance with NASDAQ, the company has faced challenges with stockholder equity requirements, indicating ongoing financial scrutiny.
• Market Competition: The AML treatment landscape is competitive, with other agents being developed that may pose challenges to tuspetinib's market entry and acceptance.

5. Notable Q&A Insights

• FDA Protocol Alignment: Questions regarding the alignment of the triplet study design with FDA expectations were addressed, confirming that the design was developed with input from key opinion leaders rather than direct FDA feedback.
• Benchmarks for Success: The management indicated that a response rate closer to 75% in the triplet study would be considered a strong indicator of success, with overall survival being the ultimate metric of interest.
• Safety and Efficacy Expectations: The team emphasized the importance of maintaining standard dosing levels of venetoclax and hypomethylating agents in the triplet therapy to ensure safety and efficacy, which differentiates tuspetinib from other agents in development.

Overall, Aptose Biosciences is positioning tuspetinib as a promising new treatment option for AML, with a focus on enhancing patient outcomes through innovative triplet therapy while navigating financial and competitive challenges.